NV-RHINOSTICS
28.9.2021 14:02:12 CEST | Business Wire | Press release
Hamilton Company and Rhinostics, an early-stage Harvard University spin-out company, are combining their respective strengths to improve the speed and quality of nasal and nasopharyngeal sample workflows from collection to processing while also reducing the need for active labor involvement. This sample type is widely used to detect antibodies and antigens in relation to the novel coronavirus, SARS-CoV-2 and many other pathogens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005022/en/
The hands-free automated workflow includes use of the RHINOstic™ nasal swab collection device and one of Hamilton’s Microlab® STAR™ , Microlab NIMBUS® , or Microlab Prep™ automated liquid handling workstations, along with the LabElite® DeCapper from Hamilton Storage Technologies. This combination of technologies alleviates common time-consuming bottlenecks in testing workflows, even during times of surging sample influx. By increasing sample throughput and reducing turnaround times, stakeholders are empowered and informed to make confident downstream decisions regarding patient treatment strategies.
The patent-pending RHINOstic nasal and buccal swab collection device consists of a polypropylene swab stick, integrated into an automation-friendly cap, and a transport tube labeled with a 2-dimensional (2D) barcode. At the point of collection, the swab minimizes patient discomfort when gathering sample. Samples collected via the RHINOstic may be shipped without use of viral transport media (VTM) to reduce reagent costs and risks of leaking or aerosol creation. Lack of VTM also eliminates the need to concentrate samples prior to analysis.
Up to 96 samples may be automatically accessioned and decapped at once using the LabElite DeCapper with a 12-channel head and conversion kit. The LabElite DeCapper may be used as a standalone device or integrated with Hamilton’s automated liquid handlers.
Hamilton’s automated liquid handlers consistently and automatically perform tedious and time-consuming pipetting and other tasks so that users may attend to higher value tasks. By reducing active labor time, efficiency and productivity are increased across the laboratory. Walkaway operation also reduces the user’s risk of biohazard exposure.
Each Hamilton automated liquid handler may be optimized with tools and programmed methods for the application at hand, including PCR, next generation sequencing (NGS), ELISA and more. User-friendly software guides any user through assay setup and processing, and when used with Hamilton pipette tips, patented Compressed O-Ring Expansion (CO-RE® ) technology creates a tight seal between pipetting mandrel and tip to support highly accurate and consistent results.
Automated sample processing using this hands-free automated workflow from Hamilton and Rhinostics may be easily scaled at any time without increasing labor, equipment or reagent costs.
About Hamilton Company:
Hamilton Company is a global enterprise with affiliates in Reno, Nevada; Franklin, Massachusetts (both USA); and Bonaduz, Switzerland and sales offices throughout the world. Hamilton Company and its affiliated entities are an industry leader in the design and manufacture of liquid handling, process analytics, robotics and automated storage solutions. For more than 60 years, Hamilton Company has been satisfying customer needs by combining quality materials with skilled workmanship to ensure the highest level of performance. Hamilton Company’s lifelong commitment to precision and quality has earned us global ISO 9001 Certification. For more information, visit www.hamiltoncompany.com .
About Rhinostics:
Rhinostics Inc. is an early stage company commercializing a simple and elegant solution to bring efficiencies and cost savings to the laboratory workflow. The RHINOstic nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. Additionally, the device allows dry shipment of respiratory samples without viral transport media, and the nasal collection allows for an easy and comfortable collection. Viral samples can be released directly into a small amount of saline, providing sample concentration of 30x or greater, providing greater standardization and improving downstream assay reliability. The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). The RHINOstic product is registered as Class I exempt medical device with the FDA and is available for purchase. To learn more, visit https://www.rhinostics.com .
All trademarks are owned and/or registered by Hamilton Company or Rhinostics in the U.S. and/or other countries. For details visit www.hamiltoncompany.com/trademarks .
Please send reader inquiries about this release directly to marketingrequest@hamiltoncompany.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005022/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 13:00:00 CEST | Press release
Largest fundraise in the firm’s history brings total capital raised to more than $75 billion Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom